These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

872 related articles for article (PubMed ID: 30717258)

  • 1. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas.
    Lee K; Lee KB; Jung HY; Yi NJ; Lee KW; Suh KS; Jang JJ
    BMC Cancer; 2017 Jun; 17(1):441. PubMed ID: 28645247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
    Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
    Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma.
    Tóth M; Wehling L; Thiess L; Rose F; Schmitt J; Weiler SME; Sticht C; De La Torre C; Rausch M; Albrecht T; Grabe N; Duwe L; Andersen JB; Köhler BC; Springfeld C; Mehrabi A; Kulu Y; Schirmacher P; Roessler S; Goeppert B; Breuhahn K
    BMC Cancer; 2021 Oct; 21(1):1079. PubMed ID: 34615513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.
    Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
    Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
    Wang H; Song X; Liao H; Wang P; Zhang Y; Che L; Zhang J; Zhou Y; Cigliano A; Ament C; Superville D; Ribback S; Reeves M; Pes GM; Liang B; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
    Hepatology; 2021 Jul; 74(1):248-263. PubMed ID: 33368437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP is a critical oncogene in human cholangiocarcinoma.
    Pei T; Li Y; Wang J; Wang H; Liang Y; Shi H; Sun B; Yin D; Sun J; Song R; Pan S; Sun Y; Jiang H; Zheng T; Liu L
    Oncotarget; 2015 Jul; 6(19):17206-20. PubMed ID: 26015398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YAP Subcellular Localization and Hippo Pathway Transcriptome Analysis in Pediatric Hepatocellular Carcinoma.
    LaQuaglia MJ; Grijalva JL; Mueller KA; Perez-Atayde AR; Kim HB; Sadri-Vakili G; Vakili K
    Sci Rep; 2016 Sep; 6():30238. PubMed ID: 27605415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics.
    Bergquist JR; Groeschl RT; Ivanics T; Shubert CR; Habermann EB; Kendrick ML; Farnell MB; Nagorney DM; Truty MJ; Smoot RL
    HPB (Oxford); 2016 Nov; 18(11):886-892. PubMed ID: 27546172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.
    Wu H; Liu Y; Jiang XW; Li WF; Guo G; Gong JP; Ding X
    Tumour Biol; 2016 Oct; 37(10):13499-13508. PubMed ID: 27465555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
    Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
    Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
    [No Abstract]   [Full Text] [Related]  

  • 13. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
    Li X; Tao J; Cigliano A; Sini M; Calderaro J; Azoulay D; Wang C; Liu Y; Jiang L; Evert K; Demartis MI; Ribback S; Utpatel K; Dombrowski F; Evert M; Calvisi DF; Chen X
    Oncotarget; 2015 Apr; 6(12):10102-15. PubMed ID: 25826091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization.
    Zhao X; Wang X; You Y; Wen D; Feng Z; Zhou Y; Que K; Gong J; Liu Z
    Exp Cell Res; 2020 Jun; 391(1):111979. PubMed ID: 32246992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
    Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
    Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma.
    Han SX; Bai E; Jin GH; He CC; Guo XJ; Wang LJ; Li M; Ying X; Zhu Q
    J Immunol Res; 2014; 2014():261365. PubMed ID: 24860833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
    Wang C; Chen C; Hu W; Tao L; Chen J
    Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
    Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
    Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers.
    Galli GG; Carrara M; Yuan WC; Valdes-Quezada C; Gurung B; Pepe-Mooney B; Zhang T; Geeven G; Gray NS; de Laat W; Calogero RA; Camargo FD
    Mol Cell; 2015 Oct; 60(2):328-37. PubMed ID: 26439301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma.
    Zhang Y; Yan S; Chen J; Gan C; Chen D; Li Y; Wen J; Kremerskothen J; Chen S; Zhang J; Cao Y
    J Cell Mol Med; 2017 Dec; 21(12):3718-3729. PubMed ID: 28815883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.